Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Steven I. McLaughlin"'
Autor:
Michael J. Beach, Jack Guy Lafontant, Patrick J. Lammie, David G. Addiss, Richard Rheingans, Marie Carmel Michel, Steven I. McLaughlin, Jeanne Radday, John Lammie
Publikováno v:
The American Journal of Tropical Medicine and Hygiene. 68:568-573
In October 2000, 71,187 persons were treated for lymphatic filariasis using albendazole and diethylcarbamazine (DEC) or DEC alone in Leogane, Haiti. We documented the frequency of adverse reactions, severity and cost of treatment. Adverse reactions w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f45de2b5cfb3a51043eb5b547c040140
https://doi.org/10.4269/ajtmh.2003.68.568
https://doi.org/10.4269/ajtmh.2003.68.568
Autor:
Mph Steven I. McLaughlin Dvm
Publikováno v:
Journal of Agromedicine. 6:87-92
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e258b3218b5e8f5d7c7c9a648197035f
https://doi.org/10.1300/j096v06n03_07
https://doi.org/10.1300/j096v06n03_07
Autor:
Michael S. Deming, Michael J. Beach, Patrick J. Lammie, Els Mathieu, Domingue J. Deodat, David G. Addiss, Steven I. McLaughlin
Publikováno v:
Transactions of the Royal Society of Tropical Medicine and Hygiene. 97(5)
In the global effort to eliminate lymphatic filariasis, annual mass treatments are conducted with diethylcarbamazine (DEC) or ivermectin, combined with albendazole. The success of this strategy depends on achieving high levels of drug coverage, which
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a0ac21efea508098093d120de728ea8
https://pubmed.ncbi.nlm.nih.gov/15307410
https://pubmed.ncbi.nlm.nih.gov/15307410
Autor:
Rogene F. Henderson, Steven I. McLaughlin, James D. Sun, Fletcher F. Hahn, J. A. Pickrell, Jack R. Harkema
Publikováno v:
Experimental and molecular pathology. 49(2)
The capacity of reduced glutathione (GSH) to protect lung tissue against ozone-induced pulmonary fibrosis was investigated. Male B6C3F 1 mice were exposed to 0, 0.2, 0.5, and 1.0 ppm ozone for 23 hr/day for 14 days. During exposures and/or for a peri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::506b8c1946464601504f74d3c51b8d38
https://pubmed.ncbi.nlm.nih.gov/2901982
https://pubmed.ncbi.nlm.nih.gov/2901982